|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Multiple sclerosis (MS) shares some risk genes with other disorders hallmarked by an autoimmune pathogenesis, most notably IL2RA and CLEC16A.
|
22130326 |
2012 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations.
|
18354419 |
2008 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
IL2RA gene polymorphism rs2104286 A>G seen in multiple sclerosis is associated with intermediate uveitis: possible parallel pathways?
|
21911588 |
2011 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
IL2RA variants are known to protect against multiple sclerosis, diabetes mellitus and RA.
|
26350950 |
2015 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A recent genome-wide study showed three additional single-nucleotide polymorphisms (SNPs), within the IL2RA and IL7RA genes respectively, also to be associated with MS.
|
18401352 |
2008 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, the FoxP3 MFIs in CD4 + CD25 + T-Cells of IFN-β1a-treated RRMS were significantly lower than the new cases of MS.
|
29589548 |
2018 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although the possibility that IL2RA is a risk factor for MS development was not confirmed in this Japanese population, IL2RA gene polymorphisms were able to modify the disease activity in female MS patients, but had no influence on either susceptibility or disease phenotype in NMO/NMOSD patients.
|
24332945 |
2014 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
An effect of the IL2RA and CD58 loci was shown in multiplex families as in sporadic MS.
|
19506219 |
2009 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
|
24076602 |
2013 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
|
24076602 |
2013 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Association between IL2RA and MS is clearly established, although the functional variation is still unknown: the effect of IL2RA might be better described by several SNPs than by a single one.
|
22085902 |
2012 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Associations of CLEC16A and IL2RA with MS were validated.
|
25903733 |
2015 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56<sup>bright</sup> natural killer cells, which seems to be the leading mechanism of action in MS.
|
28450896 |
2017 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Both signals in the two variant model for MS affect CD25 expression on distinct subpopulations of CD4+ T cells, which are key cells in the autoimmune process.
|
26106896 |
2015 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
CD2 costimulation reveals defective activity by human CD4+CD25(hi) regulatory cells in patients with multiple sclerosis.
|
21300823 |
2011 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Cytokine and cytokine receptor genes, including IL2RA, IL7R and IL12A, are known risk factors for multiple sclerosis (MS).
|
21716315 |
2012 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Daclizumab is a humanized monoclonal IgG1 antibody that binds to CD25 that has been studied for the treatment of multiple sclerosis (MS).
|
30885425 |
2019 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy.
|
22472872 |
2012 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Downregulation of Mgat1 by IL7RA*C and IL2RA*T is opposed by MGAT1 (IV(A)V(T-T)) and vitamin D(3), optimizing branching and mitigating MS risk when combined with enhanced CTLA-4 N-glycosylation by CTLA-4 Thr17.
|
21629267 |
2011 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Examination of activated T cells (CD3+CD25+) isolated from the peripheral blood of MS revealed limited numbers (20 approximately 82) of expanded clones defined by single-strand conformation polymorphism clonotype.
|
9973446 |
1999 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Flow cytometry was used to study the activation of CD4+ T cells and T cell subsets (CD25(high) and CD26(high) cells), monocytes and DCs in a cross-sectional study of 39 untreated and 29 GA-treated MS patients, the latter followed prospectively for one year.
|
22653658 |
2013 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
For example, nucleotide variation in the interleukin 7 receptor (IL7RA), the interleukin 2 receptor (IL2RA), the CD58 and the c-type lectin domain family 16 member A (CLEC16A) genes has been consistently associated with MS in several populations.
|
20450971 |
2010 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Functional investigations suggest a potential mechanism whereby increases in CD58 expression, mediated by the protective allele, up-regulate the expression of transcription factor FoxP3 through engagement of the CD58 receptor, CD2, leading to the enhanced function of CD4(+)CD25(high) regulatory T cells that are defective in subjects with MS.
|
19237575 |
2009 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Further characterization of the effect of IL2RA and IL7R genetic variants in defined MS subtypes is warranted to evaluate the effect of these genes on specific clinical outcomes and to further elucidate the mechanisms of disease onset and progression.
|
24770783 |
2014 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Furthermore, MS quiescence appears to correlate with restoration of suppressive function in memory-derived CD4(+)CD25(-)FOXP3(-) iTregs.
|
27154631 |
2016 |